BioTheraVision

CompanyUnited States

BioTheraVision develops one asset, in phase 2 (BTV100 in dry eye). Mostly small molecule acting on CHRM1 and CHRM3; based in the United States.

1
Asset
Furthest: Phase 2; 1
Trial: 0
Signals

Pipeline

1

BTV100
Muscarinic acetylcholine receptor agonist stimulating tear secretion
Phase 2, Small molecule, CHRM1, CHRM3, dry eye

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms2
Trials1
Similar companies6

Updated 8 Oct 2026 · 2 sources